This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. Our full coverage of SARS-CoV2 is available here.
Adjusting to the pandemic, NCI has developed shortcuts in the conduct of clinical trials that could make it easier to conduct clinical trials, NCI Principal Deputy Director Douglas Lowy said at the virtual meeting of the American Association for Cancer Research on COVID-19 and Cancer.
